Home/Pipeline/Asacol® (mesalazine)

Asacol® (mesalazine)

Ulcerative Colitis

ApprovedActive

Key Facts

Indication

Ulcerative Colitis

Phase

Approved

Status

Active

Company

Tillotts Pharma

About Tillotts Pharma

Tillotts Pharma is a commercial-stage, privately held specialty pharma company with a deep focus on gastroenterology. As part of the Zeria Group since 2010, it leverages a global partnership network to market its portfolio of small molecule therapeutics, primarily for inflammatory bowel disease (IBD). With over 400 employees, the company is in a growth phase, expanding its geographic reach through strategic partnerships, such as its recent deal for China.

View full company profile

Therapeutic Areas

Gastroenterology Inflammatory Bowel Disease

Other Ulcerative Colitis Drugs

Drug	Company	Phase	Status
BB265	BiomeBank	Phase 1	Active
PALI-2108	Palisade Bio	Phase 2	Advancing towards initiation
ALTB-268	AltruBio	Phase IIa	Active
AIM-HI-UC	PathAI	Clinical Trials	Active
Patient Stratification in Ulcerative Colitis	Enable Medicine	Research	Active
Mesalazine (Lifecycle Management)	Dr. Falk Pharma	Approved/Phase 3	Active
AhR Agonist Program	Azora Therapeutics	Phase 1b	Active
R-3750	Virtici	Phase 1	Active
GPR35 Inhibitor	ThirtyFiveBio	Preclinical	Active
BT-600	Biora Therapeutics	Phase 1	Active
MB310	Microbiotica	Phase 1b	Active
'1805	Revolo Biotherapeutics	Phase 2 (Planned)	Active